<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Telesis Bio Inc. — News on 6ix</title>
    <link>https://6ix.com/company/telesis-bio-inc</link>
    <description>Latest news and press releases for Telesis Bio Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 28 May 2025 13:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/telesis-bio-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c76b78dffbe2df11b73b.webp</url>
      <title>Telesis Bio Inc.</title>
      <link>https://6ix.com/company/telesis-bio-inc</link>
    </image>
    <item>
      <title>Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis</title>
      <link>https://6ix.com/company/telesis-bio-inc/news/telesis-bio-announces-licensing-agreement-130000600</link>
      <guid isPermaLink="true">https://6ix.com/company/telesis-bio-inc/news/telesis-bio-announces-licensing-agreement-130000600</guid>
      <pubDate>Wed, 28 May 2025 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, May 28, 2025--Telesis Bio Inc. (OTCMKTS: TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio’s revolutionary Gibson SOLA™ platform at its R&amp;D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs.</description>
    </item>
    <item>
      <title>Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis</title>
      <link>https://6ix.com/company/telesis-bio-inc/news/telesis-bio-secures-21-million-130000522</link>
      <guid isPermaLink="true">https://6ix.com/company/telesis-bio-inc/news/telesis-bio-secures-21-million-130000522</guid>
      <pubDate>Tue, 18 Mar 2025 13:00:00 GMT</pubDate>
      <description>SAN DIEGO, March 18, 2025--Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to</description>
    </item>
    <item>
      <title>Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market</title>
      <link>https://6ix.com/company/telesis-bio-inc/news/telesis-bio-plans-to-delist-its-securities-from-the-nasdaq-stock-market</link>
      <guid isPermaLink="true">https://6ix.com/company/telesis-bio-inc/news/telesis-bio-plans-to-delist-its-securities-from-the-nasdaq-stock-market</guid>
      <pubDate>Tue, 10 Sep 2024 20:30:11 GMT</pubDate>
      <description>Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market.</description>
    </item>
  </channel>
</rss>